Your browser doesn't support javascript.
loading
Role of colchicine to reduce NLRP3 marker in STEMI patients undergo primary PCI: A randomised controlled clinical trial.
Karim, B; Alwi, I; Pasaribu, M M; Yamin, M; Harimurti, K; Citrawijaya, H.
Afiliación
  • Karim B; Cipto Mangunkusumo National Referral Hospital/Faculty of Medicine Universitas Indonesia, Cardiology Division, Department of Internal Medicine, Indonesia. drbirrykarim@yahoo.co.id.
  • Alwi I; Cipto Mangunkusumo National Referral Hospital/Faculty of Medicine Universitas Indonesia, Cardiology Division, Department of Internal Medicine, Indonesia.
  • Pasaribu MM; Cipto Mangunkusumo National Referral Hospital/Faculty of Medicine Universitas Indonesia, Department of Clinical Pathology, Indonesia.
  • Nafrialdi; Cipto Mangunkusumo National Referral Hospital/Faculty of Medicine Universitas Indonesia, Department of Pharmacology and Therapeutic, Indonesia.
  • Yamin M; Cipto Mangunkusumo National Referral Hospital/Faculty of Medicine Universitas Indonesia, Cardiology Division, Department of Internal Medicine, Indonesia.
  • Harimurti K; Cipto Mangunkusumo National Referral Hospital/Faculty of Medicine Universitas Indonesia, Geriatric Division, Department of Internal Medicine, Indonesia.
  • Rivaldo; Cipto Mangunkusumo National Referral Hospital/Faculty of Medicine Universitas Indonesia.
  • Citrawijaya H; Cipto Mangunkusumo National Referral Hospital/Faculty of Medicine Universitas Indonesia.
Med J Malaysia ; 79(2): 146-150, 2024 Mar.
Article en En | MEDLINE | ID: mdl-38553918
ABSTRACT

INTRODUCTION:

ST-segment elevation myocardial infarction (STEMI) is a fatal disease with significant burden worldwide. Despite advanced medical treatment performed, STEMIrelated morbidity and mortality remains high due to ischemia reperfusion injury after primary angioplasty mediated by NLRP3 inflammasome. Adding colchicine expected to reduce inflammation both in vitro and in vivo. We want to evaluate the effect of colchicine administration on the NLRP3 level of STEMI patient who undergo primary cutaneous intervention (PCI). MATERIALS AND

METHODS:

Randomised controlled trial was conducted on STEMI patients who undergo PCI in two hospitals in Jakarta, 104 patients enrolled to this study, and 77 patients completed the trial. 37 patients were randomly assigned to receive colchicines (2 mg loading dose; 0.5 mg thereafter every 12 hour for 48 hours) while 40 patients received placebo. NLRP3 level was measured from venous blood at baseline (BL), after procedure (AP), dan 24-hour post procedure (24H).

RESULTS:

No NLRP3 difference was observed initially between colchicine arm and placebo arm 38,69 and 39,0138, respectively (p >0.05). Measurement conducted at 24H, patients received colchicine demonstrate reduction in NLRP3 level (37.67), while placebo arm results increase in NLRP3 level (42.89) despite not statistically significant (p >0,05).

CONCLUSION:

Colchicine addition to standard treatment of STEMI patients undergo PCI reduce NLRP3 level despite statistically insignificant.
Asunto(s)
Buscar en Google
Añadir a Mi BVS
Imprimir
XML
PubMed Links

Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Daño por Reperfusión / Intervención Coronaria Percutánea / Infarto del Miocardio con Elevación del ST / Infarto del Miocardio Límite: Humans Idioma: En Revista: Med J Malaysia Año: 2024 Tipo del documento: Article País de afiliación: Indonesia Pais de publicación: Malasia
Buscar en Google
Añadir a Mi BVS
Imprimir
XML
PubMed Links

Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Daño por Reperfusión / Intervención Coronaria Percutánea / Infarto del Miocardio con Elevación del ST / Infarto del Miocardio Límite: Humans Idioma: En Revista: Med J Malaysia Año: 2024 Tipo del documento: Article País de afiliación: Indonesia Pais de publicación: Malasia